secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0000950170-23-058199
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q3 net loss $65.7M ($0.54), cash runway into H2 2026, advances lirafugratinib and RLY-2608
--------------------------------------------------------------------------------

- Net loss of $65.7M ($0.54/share) vs $84.2M loss ($0.76) in Q3 2022; revenue $25.2M from Genentech milestone.
- Cash, equivalents, investments $810.6M; expects to fund operations into second half of 2026.
- Lirafugratinib (RLY-4008): 35% ORR in FGFR2-fusion tumors, 40% ORR in FGFR2-altered HR+/HER2- breast cancer; pivotal CCA cohort fully enrolled.
- Plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet in PI3Kα-mutant breast cancer by YE 2023; paused RLY-2139 (CDK2) development.
- Paused near-term commercial readiness for CCA to focus on tumor-agnostic opportunity; next data/regulatory update in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023058199/0000950170-23-058199-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023058199/rlay-20231102.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-058199

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer